Glatiramer
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Glatiramer: From Multiple Sclerosis to Hemoglobinopathy
One-Sentence Summary
Glatiramer (as glatiramer acetate) is an immunomodulatory therapy established for relapsing-remitting multiple sclerosis. The TxGNN model predicts it may be effective for Hemoglobinopathy, but this direction is currently supported by 0 clinical trials and only 1 tangentially related publication, and the evidence pack’s own mechanistic review found no plausible biological link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple Sclerosis (inferred from literature evidence in this pack; not formally recorded in regulatory data — original_indications is empty) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for glatiramer is not available in this evidence pack (flagged as a High-severity data gap). Based on the literature evidence collected here, glatiramer acetate is an established immunomodulatory therapy for relapsing-remitting multiple sclerosis, understood to act by inducing a Th1-to-Th2 immune deviation and expanding regulatory T-cell populations.
Hemoglobinopathies (including thalassaemias and related red-cell enzyme/membrane disorders) are structural or metabolic disorders of haemoglobin synthesis or red-cell proteins, with no established immune-mediated pathophysiology that a T-cell-modulating agent like glatiramer could plausibly address.
The evidence pack’s own mechanistic assessment explicitly concludes there is no reasonable mechanistic link between glatiramer and hemoglobinopathy. The single supporting literature reference is a case report of a patient with a past history of beta-thalassaemia who developed immune complications after discontinuing natalizumab (a different MS therapy, not glatiramer) — this is an incidental clinical detail in an unrelated case report, not evidence of a therapeutic effect. This prediction should be treated as a statistical association produced by the TxGNN knowledge-graph embedding rather than a biologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28372806 | 2017 | Case Report | Revue neurologique | Describes a 35-year-old woman with a past history of beta-thalassaemia who developed multiple immune disorders after stopping natalizumab (not glatiramer) for MS. Glatiramer is not the drug under study, and the beta-thalassaemia history is incidental to the case, not a treatment outcome. |
Australia Market Information
Glatiramer is not currently registered on the ARTG and has no marketed products in Australia (0 ARTG entries; market status: Not Marketed).
Safety Considerations
No warnings, contraindications, or drug interaction data are available for glatiramer in this evidence pack, and the drug is not currently marketed in Australia, so no TGA-approved Product Information exists locally (Blocking data gap: TFDA/TGA label warnings and contraindications). Prescribers considering this drug should consult an overseas-approved Product Information (e.g. the originator’s Copaxone PI) as an interim reference until local safety data is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction is supported only by L5 evidence (model prediction only), the evidence pack’s own mechanistic review found no plausible biological rationale, and the sole literature citation concerns a different drug and is incidental to hemoglobinopathy. With no TGA-approved PI available (drug not marketed in Australia), an S1 safety assessment cannot proceed.
To proceed, the following is needed:
- TGA/overseas Product Information (warnings, contraindications, drug interactions) — currently a Blocking data gap
- Confirmed mechanism of action data for glatiramer — currently a High-severity data gap
- Direct preclinical or clinical evidence specifically linking glatiramer to hemoglobinopathy pathophysiology
- Given the weakness of this top-ranked candidate, consider re-reviewing predicted indication #3 (female breast carcinoma, L4 evidence, 9 literature citations) as a comparison — though note that evidence there is epidemiological cancer-risk surveillance in MS cohorts, not efficacy data, and also does not currently support a “Go” decision
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.